

## Reference Data

Fiscal Year 2015  
(April 1, 2015 to March 31, 2016)

### Consolidated Earnings

• Consolidated Financial Data	P 1
• Consolidated Balance Sheets	P 2
• Consolidated P/L Statement	P 3
• Consolidated Sales Breakdown by Segment/Category	P 4
• Consolidated Operating Income by Segment	P 4
• Consolidated Sales - Leading Brands of Self-Medication Operations	P 5
• Consolidated Sales - Leading Products of Prescription Pharmaceutical Operations	P 6
• Capital Expenditure	P 7
• Depreciation and Amortization	P 7
• R&D Expenses	P 7
• Results of Major Consolidated Subsidiaries	
♦ Taisho Pharmaceutical	P 8
♦ Taisho Toyama Pharmaceutical	P 8
♦ Biofermin Pharmaceutical	P 8
• Major Subsidiaries and Affiliates	P 9
• Shareholders Information	P10
• Prescription Pharmaceutical Operations:	
New Drug Development-Taisho Pharmaceutical	P11
• Launch of New Products	P13

## Consolidated Financial Data

(Millions of yen)

	March 13 (FY2012)	March 14 (FY2013)	March 15 (FY2014)	March 16 (FY2015)	(Est.)	
					March 17(FY2016)	
					2Q(4-9)	Full year
Net sales	285,168	295,957	290,498	290,135	140,000	285,000
(YOY%)	(+5.1%)	(+3.8%)	(-1.8%)	(-0.1%)	(-4.1%)	(-1.8%)
Self-Medication operations	171,271	181,753	176,295	180,722	91,500	185,400
Prescription Pharmaceutical operations	113,896	114,204	114,202	109,413	48,500	99,600
Gross profit*	176,210	184,693	178,248	176,813	88,900	181,500
Selling, general and administrative expenses	140,873	143,009	146,273	147,935	77,900	152,000
Research and development expenses	23,331	21,874	21,554	21,768	12,200	23,400
(% Sales)	(8.2%)	(7.4%)	(7.4%)	(7.5%)	(8.7%)	(8.2%)
Advertising expenses	16,833	16,960	19,169	21,366	11,600	23,500
Sales promotion expenses	28,364	31,159	32,355	31,775	16,100	30,800
Personnel expenses	36,526	37,489	35,856	36,042	18,300	36,700
Operating income	35,337	41,683	31,974	28,878	11,000	29,500
(YOY%)	(-8.0%)	(+18.0%)	(-23.3%)	(-9.7%)	(-21.0%)	(+2.2%)
Ordinary income	44,173	51,244	39,576	36,775	14,000	36,500
(YOY%)	(-4.4%)	(+16.0%)	(-22.8%)	(-7.1%)	(-20.8%)	(-0.7%)
Profit attributable to owners of parent	26,320	32,692	24,528	22,473	9,000	24,000
(YOY%)	(+8.1%)	(+24.2%)	(-25.0%)	(-8.4%)	(-20.2%)	(+6.8%)
Comprehensive income	44,100	47,535	47,845	9,059	-	-
(YOY%)	(+67.4%)	(+7.8%)	(+0.7%)	(-81.1%)	-	-
EPS (yen)	325.26	403.18	302.57	277.75	112.63	300.37
EPS, diluted (yen)	325.22	403.07	302.42	277.59	112.56	300.17
BPS (yen)	6,975.94	7,401.61	7,892.19	7,870.04	7,928.77	8,072.90
Dividend per share (yen)**	120.00	110.00	110.00	100.00	50.00	110.00
Payout ratio	36.9%	27.3%	36.4%	36.0%	-	36.6%
Capital expenditure	12,287	10,401	5,253	8,967	5,000	8,500
Depreciation and amortization	10,951	11,042	11,561	11,117	5,200	10,800
Total assets	676,388	728,442	768,092	759,049	760,000	771,000
Shareholders' equity	578,158	611,933	653,242	643,127	648,000	660,000
Return on equity (%)***	4.8%	5.6%	4.0%	3.5%	-	3.8%
Return on assets (%)***	4.0%	4.7%	3.3%	2.9%	-	3.1%
Equity ratio (%)	83.6%	82.4%	83.3%	82.9%	83.4%	83.7%
Overseas sales	17,574	25,393	27,949	29,901	14,320	29,020
Overseas sales ratio (% of total sales)	6.2%	8.6%	9.6%	10.3%	10.2%	10.2%
Number of employees	6,370	6,381	6,609	6,517	-	-

\* After provision/reversal of reserve for returned unsold goods

\*\* Average of the beginning and year-end balance of shareholders' equity / total assets

## Consolidated Balance Sheets

(Millions of yen)

	End of FY2014		End of FY2015		change	
	(March 31, 15)	% total	(March 31, 16)	% total		
<b>(Assets)</b>						
I Current assets:	289,081	37.6%	319,670	42.1%	+30,588	
Cash and deposits	159,587		172,142		+12,555	
Notes and accounts receivable-trade	80,321		75,243		-5,078	
Marketable securities	10,038		34,316		+24,277	Transferred from investments in securities +34,217 Bond redemptions -10,000
Inventories	27,308		26,638		-670	
Deferred tax assets	6,337		6,128		-209	
Others	5,488		5,201		-286	
II Fixed assets:	479,010	62.4%	439,379	57.9%	-39,631	
(1) Tangible fixed assets:	100,366	(13.1%)	98,950	(13.0%)	-1,416	
Buildings and structures	49,109		45,979		-3,130	
Machinery and equipment	8,692		7,211		-1,480	
Land	37,500		37,473		-26	
Others	5,064		8,285		+3,221	
(2) Intangible fixed assets:	45,244	(5.9%)	38,863	(5.1%)	-6,380	
Goodwill	22,093		19,046		-3,046	
Sales rights	5,932		4,675		-1,256	
Trademarks	14,977		12,175		-2,801	
Software	1,652		2,419		+766	
Others	589		547		-42	
(3) Investments and other assets:	333,399	(43.4%)	301,565	(39.7%)	-31,834	
Investments in securities	264,642		237,213		-27,428	Bond acquisition +14,147, decrease in evaluation gain -7,154 Transferred to marketable securities -34,217
Affiliates' stocks	54,684		54,590		-94	
Net defined benefit assets	7,003		568		-6,434	Increase in retirement benefit obligations due to reduced discount rate, etc.
Deferred tax assets	5,615		7,869		+2,253	
Others	1,453		1,322		-130	
<b>Total assets</b>	<b>768,092</b>	<b>100.0%</b>	<b>759,049</b>	<b>100.0%</b>	<b>-9,043</b>	
<b>(Liabilities)</b>						
I Current liabilities:	64,230	8.4%	66,646	8.8%	+2,415	
Notes and accounts payable-trade	29,133		27,082		-2,050	
Accounts payable	14,769		16,753		+1,983	
Accrued corporate tax	3,254		5,746		+2,491	
Allowance for bonuses	3,947		3,855		-91	
Others	13,125		13,207		+82	
II Long-term liabilities:	50,619	6.6%	49,275	6.5%	-1,343	
Net defined benefit liabilities	22,385		23,713		+1,328	
Deferred taxes liabilities	19,536		16,333		-3,203	
Others	8,697		9,228		+530	
<b>Total liabilities</b>	<b>114,849</b>	<b>15.0%</b>	<b>115,922</b>	<b>15.3%</b>	<b>+1,072</b>	
<b>(Net assets)</b>						
I Shareholders' equity	597,332	77.8%	600,862	79.2%	+3,529	
Common stock	30,000	3.9%	30,000	4.0%	-	
Additional paid-in capital	15,269	2.0%	15,271	2.0%	+1	
Retained earnings	609,706	79.4%	623,255	82.1%	+13,548	Profit attributable to owners of parent +22,473 Dividend on retained earnings -8,924
Treasury stock	-57,643	-7.5%	-67,664	-8.9%	-10,020	Acquisition of treasury stock -10,097
II Accumulated other comprehensive income	42,424	5.5%	28,029	3.7%	-14,395	
Unrealized gain on securities	40,054	5.2%	35,736	4.7%	-4,318	
Deferred gains or losses on hedges	-0	-0.0%	-0	-0.0%	+0	
Foreign currency adjustment accounts	5,744	0.7%	507	0.1%	-5,237	
Remeasurements of defined benefit plans	-3,373	-0.4%	-8,213	-1.1%	-4,839	
III Subscription rights to shares	298	0.0%	357	0.0%	+58	
IV Minority interest	13,186	1.7%	13,878	1.8%	+692	
<b>Total net assets</b>	<b>653,242</b>	<b>85.0%</b>	<b>643,127</b>	<b>84.7%</b>	<b>-10,115</b>	
<b>Total liabilities and net assets</b>	<b>768,092</b>	<b>100.0%</b>	<b>759,049</b>	<b>100.0%</b>	<b>-9,043</b>	

## Consolidated P/L Statement

(Millions of yen)

	FY2014		FY2015		YOY change	
		% Sales		% Sales		
Net sales	290,498	100.0%	290,135	100.0%	-362	
Cost of sales	112,240	38.6%	113,143	39.0%	+903	
Gross profit on sales	178,258	61.4%	176,991	61.0%	-1,266	
Provision for sales returns	9		178		+168	
Gross profit	178,248	61.4%	176,813	60.9%	-1,434	
Selling, general and administrative expenses	146,273	50.4%	147,935	51.0%	+1,661	
Research and development expenses	21,554		21,768		+213	
Advertising expenses	19,169		21,366		+2,196	Increase in expenses for nurturing brand
Sales promotion expenses	32,355		31,775		-580	
Personnel expenses	35,856		36,042		+185	
Others	37,337		36,983		-354	
Operating income	31,974	11.0%	28,878	10.0%	-3,096	
Non-operating income	7,788	2.7%	8,068	2.8%	+279	Equity in earnings of entities accounted for using equity method +126
Non-operating expenses	186	0.1%	170	0.1%	-16	
Ordinary income	39,576	13.6%	36,775	12.7%	-2,800	
Extraordinary gains	1,035	0.4%	19	0.0%	-1,015	(Previous year) Gain on sales of fixed assets 1,035
Extraordinary losses	448	0.2%	985	0.3%	+536	(Previous year) Loss on disposal of fixed assets 396 (Current year) Impairment loss 850
Income before income taxes and minority interests	40,162	13.8%	35,809	12.3%	-4,352	
Income taxes	14,102	4.9%	11,927	4.1%	-2,174	
Income before minority interests	26,060	8.9%	23,882	8.2%	-2,177	
Minority interest gain of consolidated subsidiaries	1,531	0.5%	1,408	0.5%	-122	
Profit attributable to owners of parent	24,528	8.4%	22,473	7.7%	-2,055	

## Consolidated Sales Breakdown by Segment/Category

(Millions of yen)

	March 13 (FY2012)	March 14 (FY2013)	March 15 (FY2014)	March 16 (FY2015)	(Est.) March 17(FY2016)	
					2Q(4-9)	Full year
					Self-Medication operations (YOY%)	171,271 (+2.9%)
Japan	151,137	153,856	145,614	148,125	75,700	153,800
Overseas	17,561	25,379	27,939	29,875	14,300	29,000
Others	2,572	2,516	2,741	2,721	1,500	2,600
Prescription Pharmaceutical operations (YOY%)	113,896 (+8.7%)	114,204 (+0.3%)	114,202 (-0.0%)	109,413 (-4.2%)	48,500 (-10.0%)	99,600 (-9.0%)
Ethical drugs	105,437	111,289	111,594	107,215	46,200	96,100
Intermediate products, etc.	8,099	2,587	2,016	1,405	1,200	1,900
Royalty income	359	326	591	792	1,100	1,600
Total	285,168	295,957	290,498	290,135	140,000	285,000

## Consolidated Operating Income by Segment

(Millions of yen)

	March 13 (FY2012)	March 14 (FY2013)	March 15 (FY2014)	March 16 (FY2015)	(Est.) March 17(FY2016)	
					2Q(4-9)	Full year
					Self-Medication operations (YOY%)	33,510 (-5.8%)
Prescription Pharmaceutical operations (YOY%)	3,027 (-14.9%)	6,000 (+98.2%)	2,078 (-65.4%)	1,755 (-15.5%)	-1,600 (-)	1,300 (-26.0%)
Other* (YOY%)	-1,200 (-)	-1,181 (-)	-1,164 (-)	-1,271 (-)	-700 (-)	-1,400 (-)
Total	35,337	41,683	31,974	28,878	11,000	29,500

\* The "Other" segment represents the Company (a pure holding company), which is not attributable to any reportable segment.

## Consolidated Sales - Leading Brands of Self-Medication Operations

(Billions of Yen)

	March 13 (FY2012)	March 14 (FY2013)	March 15 (FY2014)	March 16		(Est.) March 17(FY2016)		
				(FY2015)	YOY	2Q(4-9)	Full year	YOY
Japan	151.1	153.9	145.6	148.1	+1.7%	75.7	153.8	+3.8%
Lipovitan series	66.8	67.5	62.1	60.5	-2.5%	33.6	60.4	-0.2%
Pabron series	26.1	26.0	25.2	24.8	-1.5%	9.9	25.5	+2.9%
RiUP series	13.9	15.6	14.9	16.5	+10.9%	7.8	16.9	+1.9%
Livita series	4.7	4.7	4.0	3.9	-2.8%	1.8	4.0	+2.9%
Gastrointestinal treatment series	4.3	4.3	4.1	4.1	+0.3%	1.9	4.1	+0.3%
NARON series	4.1	4.1	3.7	3.7	-0.9%	1.8	3.6	-2.3%
VICKS series	3.1	3.2	3.5	3.6	+3.9%	1.3	3.7	+3.2%
Colac series	3.7	3.6	3.3	3.3	+0.2%	1.6	3.4	+0.9%
ZENA series	3.1	3.3	3.0	2.7	-9.7%	1.5	3.3	+21.7%
Biofermin series <sup>*1</sup>	6.7	6.7	6.7	7.5	+11.2%	4.0	8.2	+10.2%
Overseas	17.6	25.4	27.9	29.9	+6.9%	14.3	29.0	-2.9%
Energy drinks	7.1	9.0	9.4	10.3	+9.5%	4.9	9.7	-6.1%
OTC drugs	9.6	15.5	17.6	18.4	+4.8%	9.1	18.5	+0.6%
Others	2.6	2.5	2.7	2.7	-0.7%	1.5	2.6	-4.4%

(Rounded to the nearest hundred-million)

\*1. Transferred to be sold through Taisho Pharmaceutical from January 2014. (Please refer to the July 31, 2013 news release.)

\*2. Transferred to Taisho Pharmaceutical for sales from October 2013. (Please refer to the June 28, 2013 news release.)

## Lipovitan Series: Sales Breakdown

(Billions of Yen)

	March 13 (FY2012)	March 14 (FY2013)	March 15 (FY2014)	March 16		(Est.) March 17(FY2016)		
				(FY2015)	YOY	2Q(4-9)	Full year	YOY
Lipovitan series	66.8	67.5	62.1	60.5	-2.5%	33.6	60.4	-0.2%
Lipovitan D	44.7	44.3	40.0	38.6	-3.5%	21.7	38.6	-0.1%
Others	22.0	23.2	22.1	21.9	-0.8%	11.8	21.8	-0.4%
(100mL other Lipovitans)	14.2	15.2	14.5	13.9	-3.8%	7.7	14.0	+0.7%
(50mL other Lipovitans)	7.8	8.0	7.6	8.0	+4.7%	4.1	7.8	-2.2%

(Rounded to the nearest hundred-million)

## Consolidated Sales - Leading Products of Prescription Pharmaceutical Operations

(Billions of Yen)

	March 13 (FY2012)	March 14 (FY2013)	March 15 (FY2014)	March 16		(Est.) March 17(FY2016)		
				(FY2015)	YOY	2Q(4-9)	Full year	YOY
ZOSYN	21.5	25.4	26.9	27.3	+1.4%	8.3	15.4	-43.6%
Edirol	8.8	14.1	17.2	19.8	+15.7%	10.9	22.4	+12.9%
Clarith	19.0	16.4	13.5	12.0	-10.9%	4.0	9.8	-18.3%
Palux	8.5	7.9	7.0	6.2	-11.9%	2.6	5.1	-17.8%
OZEX	8.2	7.2	6.6	5.9	-11.1%	2.0	4.6	-21.6%
Bonviva	-	1.2	3.6	4.9	+36.5%	3.1	6.6	+34.0%
Geninax	6.1	6.8	5.7	4.3	-25.1%	2.7	5.0	+16.6%
Lusefi	-	-	2.4	0.9	-63.0%	0.6	2.6	+194.5%
Biofermin	-	3.7	3.6	3.6	-2.4%	1.9	3.8	+6.8%
Yakuban and others	-	2.6	2.3	2.1	-10.0%	0.8	1.5	-27.9%
Lorcam	3.0	2.7	2.3	2.0	-13.5%	0.8	1.5	-23.4%
LUPRAC	2.3	2.3	2.2	2.1	-4.3%	0.9	1.7	-20.4%
LOQOA	-	-	-	0.4	-	0.4	1.8	+312.8%

(Rounded to the nearest hundred-million)

## Consolidated: Capital Expenditure

(Millions of yen)

	March 13 (FY2012)	March 14 (FY2013)	March 15 (FY2014)	March 16 (FY2015)	(Est.) March 17 (FY2016)	
					2Q(4-9)	Full year
					Total capital expenditure	12,287
Taisho Pharmaceutical	6,290	6,683	4,222	7,324	4,000	6,700
Omiya Factory	912	812	920	868	480	1,000
Hanyu Factory	20	99	61	21	20	60
Okayama Factory	95	26	64	28	10	70
Research Center	2,084	1,726	1,879	1,053	330	950
Others	3,177	4,018	1,296	5,351	3,160	4,620
Other subsidiaries	5,996	3,718	1,031	1,642	1,000	1,800

## Consolidated: Depreciation and Amortization

(Millions of yen)

	March 13 (FY2012)	March 14 (FY2013)	March 15 (FY2014)	March 16 (FY2015)	(Est.) March 17 (FY2016)	
					2Q(4-9)	Full year
					Depreciation and amortization	10,951
Cost of sales	3,518	4,033	4,163	3,823	1,800	3,700
SGA expenses	7,432	7,009	7,398	7,293	3,400	7,100

## Consolidated: R&D Expenses

(Millions of yen)

	March 13 (FY2012)	March 14 (FY2013)	March 15 (FY2014)	March 16 (FY2015)	(Est.) March 17 (FY2016)	
					2Q(4-9)	Full year
					Total R&D expenses	23,331
Self-Medication operations	5,908	5,790	5,502	5,497	3,300	6,200
Prescription Pharmaceutical operations	17,423	16,084	16,051	16,270	8,900	17,200

## Results of Major Consolidated Subsidiaries

### Sales and earnings of Taisho Pharmaceutical

(Billions of Yen)

	March 13 (FY2012)	March 14 (FY2013)	March 15 (FY2014)	March 16		(Est.) March 17(FY2016)		
				(FY2015)	YOY	2Q(4-9)	Full year	YOY
Net Sales	195	197	198	198	+0.2%	101	207	+4.5%
Self-Medication	145	149	147	150	+2.0%	77	156	+3.7%
Prescription Pharmaceutical	50	47	51	48	-4.9%	24	52	+6.7%
Operating income	28	32	21	20	-6.0%	7	21	+9.6%
Ordinary income	31	39	25	24	-1.4%	11	26	+5.5%
Profit	22	27	17	18	+2.6%	9	20	+10.7%

(Rounded to the nearest hundred-million)

### Sales and earnings of Taisho Toyama Pharmaceutical

(Billions of Yen)

	March 13 (FY2012)	March 14 (FY2013)	March 15 (FY2014)	March 16		(Est.) March 17(FY2016)		
				(FY2015)	YOY	2Q(4-9)	Full year	YOY
Net Sales	100	107	112	107	-3.9%	46	96	-10.4%
Operating income	2	2	4	3	-25.4%	1	2	-14.8%
Ordinary income	2	3	4	3	-25.0%	1	2	-15.0%
Profit	1	1	2	1	-24.8%	1	2	+6.3%

(Rounded to the nearest hundred-million)

Sales and earnings of Taisho Toyama Pharmaceutical are included in the consolidated results of Prescription Pharmaceutical operati

### Sales and earnings of Biofermin Pharmaceutical

(Billions of Yen)

	March 13 (FY2012)	March 14 (FY2013)	March 15 (FY2014)	March 16		(Est.) March 17(FY2016)		
				(FY2015)	YOY	2Q(4-9)	Full year	YOY
Net Sales	10	11	11	10	-10.9%	5	10	+6.6%
Self-Medication	7	7	7	7	-6.5%	3	7	+1.7%
Prescription Pharmaceutical	4	4	4	3	-19.0%	2	4	+17.1%
Operating income	3	3	3	2	-32.3%	1	2	+3.2%
Ordinary income	3	3	4	2	-32.9%	1	2	+3.2%
Profit	2	2	2	2	-30.1%	1	2	+6.9%

(Rounded to the nearest hundred-million)

## Major Subsidiaries and Affiliates

(As of March 31, 2016)

Company	Address	Capital	Business	Ownership <sup>*</sup>
(1) Consolidated subsidiaries				%
Taisho Pharmaceutical Co.,Ltd.	Tokyo, Japan	,000 Yen 29,804,450	SMG PD	100.0
MEJIRO KOSAN Co., Ltd.	Tokyo, Japan	,000 Yen 600,000	SMG	100.0
Taisho Okinawa Co.,Ltd.	Okinawa, Japan	,000 Yen 50,000	SMG	100.0
Taisho M.T.C. Co.,Ltd.	Tokyo, Japan	,000 Yen 400,000	SMG	60.0
Taisho Pharmaceutical Logistics Co.,Ltd.	Saitama, Japan	,000 Yen 30,000	SMG	100.0
Biofermin Pharmaceutical Co., Ltd.	Hyogo, Japan	,000 Yen 1,227,000	SMG PD	64.0
Taisho Toyama Pharmaceutical Co.,Ltd.	Tokyo, Japan	,000 Yen 2,000,000	PD	70.3
TAISHO ACTIVE HEALTH Co., Ltd.	Tokyo, Japan	,000 Yen 100,000	SMG	55.0
TOKUHON Corporation	Tokyo, Japan	,000 Yen 300,000	SMG PD	100.0
Taisho Pharmaceutical (Taiwan) Co.,Ltd.	Taiwan	,000 NT\$ 200,000	SMG	100.0
Taisho Pharmaceutical California Inc.	U.S.A.	,000 US\$ 41,050	SMG	100.0
Taisho Pharmaceuticals (Philippines), Inc.	Philippines	,000 Peso 18,900	SMG	100.0
Taisho Co.,Ltd. Shanghai	China	,000 CNY 132,621	SMG	100.0
Taisho Vietnam Co.,Ltd.	Vietnam	,000 VND 170,754,300	SMG	100.0
Taisho Pharmaceutical (H.K.) Ltd.	China	,000 HK\$ 163,000	SMG	100.0
Osotspa Taisho Pharmaceutical Co., Ltd.	Thailand	,000 THB 100,000	SMG	60.0
Taisho Pharmaceutical R&D Inc.	U.S.A.	,000 US\$ 4,000	PD	100.0
PT. Taisho Pharmaceutical Indonesia Tbk	Indonesia	,000 rupiah 10,240,000	SMG	98.0
Taisho Pharmaceutical Singapore Private Limited	Singapore	,000 US\$ 1,000	SMG	100.0
Hoepharm Holdings Sdn.Bhd.	Malaysia	,000 MYR 32,380	SMG	100.0
Compañía Internacional de Comercio, S.A.P.I. de C.V.	Mexico	,000 MXN 122,467	SMG	100.0
(2) Equity accounting method				
Toyama Chemical Co.,Ltd.	Tokyo, Japan	,000 Yen 10,000,000	PD	34.0
Yomeishu Seizo Co., Ltd.	Tokyo, Japan	,000 Yen 1,650,000	SMG	24.1

SMG=Self-Medication operations PD=Prescription Pharmaceutical operations

\*Ownership: including the portion of indirect ownership

## Shareholders Information (as of end of March 2016)

### Major Shareholders

(Thousands of Shares)

Shareholders	Number of shares	% of total
The Uehara Memorial Foundation	12,900	16.13%
Shoji Uehara	9,974	12.47%
Uehara Museum	3,900	4.88%
Sumitomo Mitsui Banking Corp.	3,000	3.75%
The Bank of Tokyo-Mitsubishi UFJ, Ltd.	3,000	3.75%
Akira Uehara	2,143	2.68%
Sumitomo Chemical Co., Ltd.	2,109	2.64%
Kajima Corporation	1,650	2.06%
Japan Trustee Services Bank, Ltd. (Trust account)	1,550	1.94%
Japan Trustee Services Bank, Ltd. (Sumitomo Mitsui Trust Bank, Limited ReTrust Account/ Sumitomo Chemical Company, Limited Employee Pension Trust Account)	1,530	1.91%

Shares less than one thousand are rounded down.

Treasury stock of 10,160 thousand shares are excluded from the above as these shares do not have voting right

The shareholding ratio is calculated excluding treasury stock. (Rounded to the nearest second decimal place)

### Distribution of Ownership Among Shareholders

	% of total
Financial Institutions	20.97%
Financial Instruments Firms	0.26%
Other companies	38.86%
Foreign Companies	10.56%
Individuals and Others	29.35%
Total	100.00%

The shareholder composition is calculated excluding treasury stock of 10,160 thousand shares.

(Rounded to the nearest second decimal place)

# Prescription Pharmaceutical Operations: New Drug Development - Taisho Pharmaceutical

As of May 16, 2016

## In Japan

### Phase 2

#### TS-091 (Oral)

- < Application > Central disorders of hypersomnolence
- < Development > In-house

#### TS-152 (Injection)

- < Application > Rheumatoid arthritis
- < Development > In-license (Licensor: Ablynx)
- < Description > Anti-TNF(Tumor Necrosis Factor)- $\alpha$  antibody
- < Remarks > Generic name: Ozoralizumab

#### TS-141 (Oral)

- < Application > Childhood Attention-Deficit/Hyperactivity Disorder
- < Development > In-house

## Overseas

### Phase 1

#### TS-071 (Oral)

- < Target disease > Type 2 diabetes
- < In-house/Licensed-in > In-house
- < Description > Sodium-glucose cotransporter 2 (SGLT2) inhibitor
- < Remarks > Generic name: Luseogliflozin Hydrate  
In Japan: Launched on May 23, 2014 (Product name: Lusefi)

#### TS-121 (Oral)

- < Target disease > Depression
- < In-house/Licensed-in > In-house

#### TS-091 (Oral)

- < Target disease > Central disorders of hypersomnolence
- < In-house/Licensed-in > In-house

#### TS-134 (Oral)

- < Target disease > Schizophrenia
- < In-house/Licensed-in > In-house

## Prescription Pharmaceutical Operations: New Drug Development - Taisho Pharmaceutical

As of May 16, 2016

### Changes Since FY2015 3Q Earnings Announcement (Feb 3, 2016)

#### In Japan: Bonviva (Oral)

- < Application > Osteoporosis
- < Development > Co-development with Chugai Pharmaceutical
- < Description > Antiresorptive bisphosphonate
- < Remarks > Generic name: Ibandronate Sodium Hydrate  
Pharmaceutical development code: CT-064
  
- < Changes > Removed from pipeline due to launch of product on April 21, 2016.

#### In Japan: TS-141 (Oral)

- < Application > Childhood Attention-Deficit/Hyperactivity Disorder
- < In-house/Licensed-in > In-house
  
- < Changes > Added to Phase 2

## Launch of New Products

As of May 16, 2016

### Self-Medication Operations

#### **RAIZIN Green Wing**

- < Description > A strongly carbonated, refreshing energy drink with a crisp and clear flavor.  
A fresh aroma arises when the can is opened, followed by a mild sweetness and crisp tanginess spreading comfortably on the palate.
- < Launch > March 2016

#### **KOBARASAPŌTO Grapefruit Flavor**

- < Description > An innovative diet support beverage based on patented Kobara Sensor (stomach acid detection) technology. Features a refreshing grapefruit flavor and light carbonation, with a low calorie content of 31 kcal per can.
- < Launch > March 2016

#### **ALFE neo \*Relaunched**

- < Description > Despite increasing the iron content, the product is enhanced with masking technology to make it even easier to drink. A caffeine-free, low-calorie mini-drink, with the calorie content reduced from 27 kcal to 5 kcal per bottle.
- < Launch > April 2016

#### **Lipovitan D limited-edition Father's Day bottle**

- < Description > A limited-edition bottle featuring a Father's Day illustration and a message of printed on the Lipovitan D label. Launched with a super casual package design. Sold in a limited quantity, for a limited period only, via Taisho Pharmaceutical Direct, a mail order and direct sales service.
- < Launch > May 2016

### Prescription Pharmaceutical Operations

#### **Bonviva Tablet**

- < Description > An ibandronate sodium hydrate oral tablet, serving as a bisphosphonate antiresorptive agent. A reformulation of the Bonviva injection already launched as an osteoporosis treatment.
- < Launch > April 2016